Literature DB >> 21138865

Benign mesenchymal stromal cells in human sarcomas.

Alexei Morozov1, Robert J Downey, John Healey, Andre L Moreira, Emil Lou, Anna Franceschino, Yildirim Dogan, Roland Leung, Mark Edgar, Michael LaQuaglia, Robert G Maki, Malcolm A S Moore.   

Abstract

PURPOSE: Recent evidence suggests that at least some sarcomas arise through aberrant differentiation of mesenchymal stromal cells (MSCs), but MSCs have never been isolated directly from human sarcoma specimens. EXPERIMENTAL
DESIGN: We examined human sarcoma cell lines and primary adherent cultures derived from human sarcoma surgical samples for features of MSCs. We further characterized primary cultures as either benign or malignant by the presence of tumor-defining genetic lesions and tumor formation in immunocompromised mice.
RESULTS: We show that a dedifferentiated liposarcoma cell line DDLS8817 posesses fat, bone, and cartilage trilineage differentiation potential characteristic of MSCs. Primary sarcoma cultures have the morphology, surface immunophenotype, and differentiation potential characteristic of MSCs. Surprisingly, many of these cultures are benign, as they do not form tumors in mice and lack sarcoma-defining genetic lesions. Consistent with the recently proposed pericyte origin of MSCs in normal human tissues, sarcoma-derived benign MSCs (SDBMSCs) express markers of pericytes and cooperate with endothelial cells in tube formation assays. In human sarcoma specimens, a subset of CD146-positive microvascular pericytes expresses CD105, an MSC marker, whereas malignant cells largely do not. In an in vitro coculture model, SDBMSCs as well as normal human pericytes markedly stimulate the growth of sarcoma cell lines.
CONCLUSIONS: SDBMSCs/pericytes represent a previously undescribed stromal cell type in sarcoma that may contribute to tumor formation. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21138865      PMCID: PMC3820159          DOI: 10.1158/1078-0432.CCR-09-2886

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  40 in total

1.  Perivascular multipotent progenitor cells in human organs.

Authors:  Mihaela Crisan; Chien-Wen Chen; Mirko Corselli; Gabriella Andriolo; Lorenza Lazzari; Bruno Péault
Journal:  Ann N Y Acad Sci       Date:  2009-09       Impact factor: 5.691

2.  Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies.

Authors:  A Eberhard; S Kahlert; V Goede; B Hemmerlein; K H Plate; H G Augustin
Journal:  Cancer Res       Date:  2000-03-01       Impact factor: 12.701

Review 3.  The (in) auspicious role of mesenchymal stromal cells in cancer: be it friend or foe.

Authors:  S Kidd; E Spaeth; A Klopp; M Andreeff; B Hall; F C Marini
Journal:  Cytotherapy       Date:  2008       Impact factor: 5.414

Review 4.  Co-evolution of tumor cells and their microenvironment.

Authors:  Kornelia Polyak; Izhak Haviv; Ian G Campbell
Journal:  Trends Genet       Date:  2008-12-04       Impact factor: 11.639

Review 5.  Cancer-associated fibroblasts and tumor growth--bystanders turning into key players.

Authors:  Arne Ostman; Martin Augsten
Journal:  Curr Opin Genet Dev       Date:  2009-02-09       Impact factor: 5.578

6.  Identification of cancer stem cells in Ewing's sarcoma.

Authors:  Mario-Luca Suvà; Nicolò Riggi; Jean-Christophe Stehle; Karine Baumer; Stéphane Tercier; Jean-Marc Joseph; Domizio Suvà; Virginie Clément; Paolo Provero; Luisa Cironi; Maria-Chiara Osterheld; Louis Guillou; Ivan Stamenkovic
Journal:  Cancer Res       Date:  2009-02-10       Impact factor: 12.701

7.  Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma.

Authors:  Cecile Rouleau; Maritza Curiel; William Weber; Robert Smale; Leslie Kurtzberg; James Mascarello; Carol Berger; Gina Wallar; Rebecca Bagley; Nakayuki Honma; Kazumasa Hasegawa; Isao Ishida; Shiro Kataoka; Beth L Thurberg; Khodadad Mehraein; Bruce Horten; Glenn Miller; Beverly A Teicher
Journal:  Clin Cancer Res       Date:  2008-11-15       Impact factor: 12.531

8.  Heterogeneity of angiogenesis and blood vessel maturation in cartilage tumors.

Authors:  Thomas Kalinski; Saadettin Sel; Irina Kouznetsova; Martin Röpke; Albert Roessner
Journal:  Pathol Res Pract       Date:  2009-01-20       Impact factor: 3.250

9.  CD146(+) bone marrow osteoprogenitors increase in the advanced stages of primary myelofibrosis.

Authors:  Claudio Tripodo; Andrea Di Bernardo; Maria Paola Ternullo; Carla Guarnotta; Rossana Porcasi; Sabrina Ingrao; Umberto Gianelli; Emanuela Boveri; Emilio Iannitto; Giovanni Franco; Ada Maria Florena
Journal:  Haematologica       Date:  2008-11-23       Impact factor: 9.941

Review 10.  Migratory neighbors and distant invaders: tumor-associated niche cells.

Authors:  Jared Wels; Rosandra N Kaplan; Shahin Rafii; David Lyden
Journal:  Genes Dev       Date:  2008-03-01       Impact factor: 11.361

View more
  9 in total

1.  Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.

Authors:  Srikanth R Ambati; Eloisi Caldas Lopes; Kohji Kosugi; Ullas Mony; Ahmet Zehir; Smit K Shah; Tony Taldone; Andre L Moreira; Paul A Meyers; Gabriela Chiosis; Malcolm A S Moore
Journal:  Mol Oncol       Date:  2013-12-15       Impact factor: 6.603

2.  Dentine matrix protein 1 (DMP-1) is a marker of bone formation and mineralisation in soft tissue tumours.

Authors:  Y Inagaki; T G Kashima; E S Hookway; Y Tanaka; A B Hassan; U Oppermann; N A Athanasou
Journal:  Virchows Arch       Date:  2015-01-29       Impact factor: 4.064

Review 3.  Endoglin for targeted cancer treatment.

Authors:  Lee S Rosen; Michael S Gordon; Francisco Robert; Daniela E Matei
Journal:  Curr Oncol Rep       Date:  2014-02       Impact factor: 5.075

4.  Heterogeneity and immunophenotypic plasticity of malignant cells in human liposarcomas.

Authors:  Yan Zhang; Eric D Young; Katelynn Bill; Roman Belousov; Tingsheng Peng; Alexander J Lazar; Raphael E Pollock; Paul J Simmons; Dina Lev; Mikhail G Kolonin
Journal:  Stem Cell Res       Date:  2013-05-12       Impact factor: 2.020

5.  Mesenchymal Tumors Can Derive from Ng2/Cspg4-Expressing Pericytes with β-Catenin Modulating the Neoplastic Phenotype.

Authors:  Shingo Sato; Yuning J Tang; Qingxia Wei; Makoto Hirata; Angela Weng; Ilkyu Han; Atsushi Okawa; Shu Takeda; Heather Whetstone; Puvindran Nadesan; David G Kirsch; Jay S Wunder; Benjamin A Alman
Journal:  Cell Rep       Date:  2016-07-14       Impact factor: 9.423

6.  Surface-enhanced resonance Raman scattering nanostars for high-precision cancer imaging.

Authors:  Stefan Harmsen; Ruimin Huang; Matthew A Wall; Hazem Karabeber; Jason M Samii; Massimiliano Spaliviero; Julie R White; Sébastien Monette; Rachael O'Connor; Kenneth L Pitter; Stephen A Sastra; Michael Saborowski; Eric C Holland; Samuel Singer; Kenneth P Olive; Scott W Lowe; Ronald G Blasberg; Moritz F Kircher
Journal:  Sci Transl Med       Date:  2015-01-21       Impact factor: 17.956

7.  Tunneling Nanotubes: A new paradigm for studying intercellular communication and therapeutics in cancer.

Authors:  Emil Lou; Sho Fujisawa; Afsar Barlas; Yevgeniy Romin; Katia Manova-Todorova; Malcolm A S Moore; Subbaya Subramanian
Journal:  Commun Integr Biol       Date:  2012-07-01

8.  Tumor versus stromal cells in culture--survival of the fittest?

Authors:  Krishna M Talasila; Narve Brekka; Kjersti Mangseth; Daniel Stieber; Lasse Evensen; Gro V Rosland; Anja Torsvik; Marek Wagner; Simone P Niclou; Rupavathana Mahesparan; Olav K Vintermyr; Rolf Bjerkvig; Janice M Nigro; Hrvoje Miletic
Journal:  PLoS One       Date:  2013-12-02       Impact factor: 3.240

9.  Ewing's Sarcoma: An Analysis of miRNA Expression Profiles and Target Genes in Paraffin-Embedded Primary Tumor Tissue.

Authors:  Antonina Parafioriti; Caterina Bason; Elisabetta Armiraglio; Lucia Calciano; Primo Andrea Daolio; Martina Berardocco; Andrea Di Bernardo; Alessia Colosimo; Roberto Luksch; Anna C Berardi
Journal:  Int J Mol Sci       Date:  2016-04-30       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.